STEK — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-06-22

• Globe Net Wireless Corp was incorporated in the State of Nevada, USA on September 4, 2009 with ticker symbol “GNTW”. On August 19, 2021, Stemtech Corporation (“Stemtech”), a (Delaware corporation), entered into a Merger Agreement (the “Merger Agreement”) with Globe Net Wireless Corp. (“Globe Net” or…

• Stemtech’s patented, advanced Stem Cell Nutrition formulations are one-of-a-kind natural products designed to help support the three most important aspects of stem cell physiology found in our RCM System: 1) Releasing the body’s own stem cells slowing down the bodies aging process; 2) their Circulat…

• In December 2022, our new Cellect One® Rapid Renew Stem Cell Peptide Night Cream. The Night Cream is a Stemtech proprietary formula containing an FDA patented ingredient, Red Oak Bark, which enables deep penetration to promote good skin health. In 2025, we introduced Cellect One® Shield: HOCL (Hypoc…

• While sales of products obviously create the cash flow, our real business model is not just “sales”, but lateral penetration. We do this through our IBPs - “Independent Business Partners” Sales Force, and we invest much energy in growing our IBPs. Post funding, Stemtech is projecting the addition of…

• During the three months ended March 31, 2026 and 2025, net sales were $462,957 and $868,046, respectively, representing a decrease of $405,089. The decline in net sales was primarily attributable to a continued reduction in available inventory across certain key product lines, which constrained the …

Text removed vs the prior filing · source: 10-Q · 2025-11-19

• Stemtech Corporation was incorporated in Nevada on March 4, 2009, and became a publicly traded entity after its registration statement on Form S-1 was declared effective on May 15, 2013. On August 19, 2021, Stemtech acquired 100% of Stemtech Corporation, resulting in the issuance of 37,060,000 share…

• Stemtech has pioneered a unique category of Stem Cell Nutrition, offering natural, patented dietary supplements that support the three key aspects of stem cell physiology: the release, circulation, and migration of adult stem cells. Our products are formulated with botanicals and other clinically do…

• · Stemrelease3™ – the release of the body’s own adult stem cells

• · StemFlo Advanced® - circulation of adult stem cells through the bloodstream

• · MigraStem® - migration of stem cells from the bloodstream into the tissues in need of support

Text added vs the prior filing · source: 10-Q · 2026-06-22

• On August 6, 2019, the former CEO prior to the Company’s Bankruptcy, filed a lawsuit against the Company’s subsidiary Stemtech HealthSciences, alleging unpaid salary and vacation time dating to a period predating the Company’s current management team taking control in 2018. Plaintiff’s claim is in t…

• In the opinion of management, the resolution of this matter, if any, will not have a material adverse impact on the Company’s consolidated financial position or consolidated results of operations.

Text removed vs the prior filing · source: 10-Q · 2025-11-19

• The former CEO of Stemtech HealthSciences Corp. has claimed approximately $267,000 in unpaid compensation relating to periods before current management took over in 2018. The Company disputes the claim and has filed a counterclaim. The case is ongoing.

• Based on management’s assessment, a loss of $267,000 is considered probable, and this amount has been fully accrued as of September 30, 2025. The Company cannot estimate any additional loss at this time.

• Some lenders under the Company’s Merchant Cash Advance (“MCA”) agreements have filed legal actions alleging defaults and demanding repayment. These matters are still at an early stage.

• The Company continues to carry the entire MCA balances as liabilities. Management believes that any loss above the recorded amounts is reasonably possible, but the amount of any additional loss cannot be estimated at this time. The Company intends to defend these claims.

• These matters may increase legal expenses or accelerate payments, which could affect liquidity. Management is taking steps to address these uncertainties through planned financing and cost controls.